Consensus $7.98. The company said, “Gilead (GILD) does not exclude acquired IPR&D expenses from its non-GAAP financial measures. This transaction with Kymera is expected to reduce Gilead’s GAAP and non-GAAP 2025 EPS by approximately $0.02 – $0.03.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead, Kymera enter license agreement for molecular glue degrader program
- Expected breakthrough year against H.I.V. fades as U.S. pulls support, NYT says
- Citi views Yeztugo as ‘key growth driver’ for Gilead
- Oppenheimer sees limited near-term impact from Gilead HIV approval
- BMO says lenacapavir approval for prevention a ‘major win’ for Gilead